Incyte Corp.
Incyte Corporation (INCY)
Overview
Incyte Corporation is an American biopharmaceutical company headquartered in Wilmington, Delaware, founded in 2002. It discovers, develops, and commercializes prescription medicines primarily in oncology/hematology and, increasingly, inflammation and autoimmunity/dermatology. Incyte operates internationally, including a European headquarters in Morges, Switzerland, employs roughly 2,600-2,850 people, and generated approximately $4.24 billion in revenue in 2024, growing to roughly $5.1-5.8 billion on a trailing basis in 2025-2026. Its market capitalization sits around $26 billion, and it trades on Nasdaq as an S&P 500 component classified in the biotechnology industry.
What They Do & How They Make Money
Incyte makes money almost entirely by discovering, manufacturing, and selling patent-protected prescription drugs, primarily for blood cancers, other oncology indications, and inflammatory/dermatologic conditions. Its foundational and still-dominant product is ruxolitinib, sold in the U.S. as the oral drug Jakafi for myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease, and as the topical cream Opzelura for atopic dermatitis and vitiligo. Jakafi/Opzelura together account for the large majority of Incyte's product revenue. Beyond direct U.S. sales, Incyte licenses ruxolitinib to Novartis, which markets it outside the U.S. under the brand Jakavi — this generates a meaningful, high-margin royalty revenue stream on top of Incyte's own product sales, a hallmark of Incyte's business model (out-licensing ex-U.S. or specific-indication rights while retaining core U.S. commercial rights). The company supplements its flagship franchise with a growing portfolio of newer approved oncology drugs (Pemazyre for bile duct cancer, Monjuvi/Minjuvi for lymphoma, Tabrecta for lung cancer, Iclusig for leukemia, Zynyz for Merkel cell carcinoma, and Niktimvo for chronic graft-versus-host disease) and licenses select older assets (e.g., it holds rights related to Olumiant/baricitinib in some contexts). Growth is pursued through continued expansion of Jakafi/Opzelura into new indications, launches of newer drugs, a deep clinical pipeline in oncology and inflammation/autoimmunity, and disciplined bolt-on acquisitions (such as Villaris Therapeutics in 2022 and Escient Pharmaceuticals in 2024) that add pipeline assets in adjacent therapeutic areas.
Business Segments
Incyte does not organize its business into multiple operating segments in the way an industrial conglomerate does — as a biopharmaceutical company, it reports as a single operating segment but breaks out revenue by product/source in its financial disclosures:
- Jakafi (ruxolitinib, oral) net product revenue — U.S. sales for myelofibrosis, polycythemia vera, and GVHD; historically the largest single revenue contributor.
- Opzelura (ruxolitinib cream) net product revenue — U.S. sales for atopic dermatitis and vitiligo; one of the company's fastest-growing products.
- Other marketed oncology products — Pemazyre, Monjuvi/Minjuvi, Tabrecta, Iclusig, Zynyz, and Niktimvo, a smaller but expanding collection of revenue contributors as they scale post-launch.
- Royalties — royalty income earned primarily from Novartis on ex-U.S. sales of Jakavi (ruxolitinib) and from other licensing/collaboration arrangements; a high-margin, largely pass-through revenue stream requiring minimal incremental commercial spend.
- Collaboration and milestone revenue — payments from partners for licensed compounds and research collaborations.
Because Jakafi has historically generated the substantial majority of total revenue, Incyte's near-term financial results remain heavily dependent on that single franchise, even as the company works to diversify.
Competitors
- Myelofibrosis/JAK-inhibitor space: GSK's momelotinib (Ojjaara), and Sobi/CTI Biopharma's pacritinib (Vonjo), both approved competitors targeting overlapping myeloproliferative-neoplasm patient populations against Jakafi.
- Atopic dermatitis/topical anti-inflammatory space (Opzelura): Pfizer (Cibinqo, an oral JAK inhibitor), AbbVie (Rinvoq), and topical/systemic alternatives from other dermatology-focused companies.
- Oncology portfolio generally: large diversified oncology players such as Bristol Myers Squibb, Novartis (which is simultaneously Incyte's ex-U.S. licensing partner for Jakavi and a competitor in oncology more broadly), Merck, AbbVie, and numerous specialty/biotech oncology companies competing in specific tumor types (biliary tract cancer, lymphoma, lung cancer, leukemia).
- Broader biopharma competition: large-cap pharma and biotech companies compete for the same clinical development talent, in-licensing/acquisition targets, and physician mindshare across oncology and inflammation/immunology.
Competitive Position
Incyte's core competitive advantage is its first-mover, durable franchise in JAK-inhibitor therapy for myeloproliferative neoplasms — Jakafi has held a dominant market position in myelofibrosis for over a decade, supported by strong physician familiarity, a broad label, and continued lifecycle management (including the topical Opzelura extension into large dermatology markets). The Novartis ex-U.S. licensing arrangement gives Incyte global revenue exposure and high-margin royalty income without the cost of building out its own international commercial infrastructure. Incyte has also successfully diversified beyond Jakafi with a growing suite of newer oncology and inflammation drugs, and it maintains a substantial clinical pipeline spanning oncology, dermatology, and other inflammatory/autoimmune indications, aided by targeted M&A that adds new therapeutic platforms.
Key risks include heavy revenue concentration in the Jakafi/ruxolitinib franchise, which faces eventual patent expiration/loss of exclusivity risk and encroaching competition from newer JAK inhibitors and non-JAK mechanisms in myelofibrosis and atopic dermatitis. Biopharma-specific risks apply broadly: clinical trial failures for pipeline candidates, regulatory approval uncertainty, pricing and reimbursement pressure (including U.S. drug-pricing policy and the Inflation Reduction Act's Medicare price-negotiation provisions, which can affect high-revenue drugs like Jakafi over time), and the need to keep replenishing the pipeline through R&D or acquisitions to sustain growth once the core franchise matures. Incyte's historical net income has also shown significant year-to-year volatility (including a sharp dip in 2024 net income despite steady revenue growth), reflecting the impact of R&D spending, acquisition-related charges, and other one-time items typical of a mid-cap biopharmaceutical company reinvesting in its pipeline.